Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma

被引：0
|
作者：
Albrecht, L. J. [1 ]
Dimitriou, F. [2 ]
Grover, P. [3 ]
Hassel, J. C. [4 ,5 ]
Erdmann, M. [6 ]
Forschner, A. [7 ]
Johnson, D. [8 ,9 ]
Livingstone, E. [1 ]
Roesch, A. [1 ,10 ]
Ugurel, S. [1 ]
Schulz, C. [4 ,5 ]
Berking, C. [6 ]
Menzies, A. M. [3 ,11 ,12 ]
Long, G. V. [11 ,12 ]
Dummer, R. [2 ]
Schadendorf, D. [1 ,10 ]
Zimmer, L. [1 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia
[4] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[6] Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany
[7] Univ Hosp Tuebingen, Dept Dermatol, Tubingen, Germany
[8] VUMC, Dept Med, Div Hematol & Oncol, Nashville, TN USA
[9] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA
[10] German Canc Consortium DKTK, Essen, Germany
[11] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, Australia
[12] Univ Sydney, Fac Med & Hlth, Sydney, Australia
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP023
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [1] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
    Zimmer, Lisa
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica Cecile
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas Buckner
    Livingstone, Elisabeth
    Roesch, Alexander
    Ugurel, Selma
    Schulz, Carsten
    Berking, Carola
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Schadendorf, Dirk
    Albrecht, Lea Jessica
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
    Albrecht, Lea Jessica
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica C.
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas B.
    Varaljai, Renata
    Lodde, Georg
    Placke, Jan Malte
    Krefting, Frederik
    Zaremba, Anne
    Ugurel, Selma
    Roesch, Alexander
    Schulz, Carsten
    Berking, Carola
    Poettgen, Christoph
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Livingstone, Elisabeth
    Schadendorf, Dirk
    Zimmer, Lisa
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [3] Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
    Huynh, Sandra
    Mortier, Laurent
    Dutriaux, Caroline
    Maubec, Eve
    Boileau, Marie
    Dereure, Olivier
    Leccia, Marie-Therese
    Arnault, Jean-Philippe
    Brunet-Possenti, Florence
    Aubin, Francois
    Dreno, Brigitte
    Beylot-Barry, Marie
    Lebbe, Celeste
    Lefevre, Wendy
    Delyon, Julie
    [J]. CANCERS, 2020, 12 (06) : 1 - 11
  • [4] Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
    Julia R. Dixon-Douglas
    Riyaben P. Patel
    Pretashini M. Somasundram
    Grant A. McArthur
    [J]. Current Oncology Reports, 2022, 24 : 1071 - 1079
  • [5] Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
    Dixon-Douglas, Julia R.
    Patel, Riyaben P.
    Somasundram, Pretashini M.
    McArthur, Grant A.
    [J]. CURRENT ONCOLOGY REPORTS, 2022, 24 (08) : 1071 - 1079
  • [6] Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
    da Silva, I. Pires
    Zakria, D.
    Ahmed, T.
    Trojaniello, C.
    Dimitriou, F.
    Allayous, C.
    Gerard, C.
    Zimmer, L.
    Lo, S.
    Michielin, O. A.
    Lebbe, C.
    Mangana, J.
    Ascierto, P. A.
    Johnson, D.
    Carlino, M.
    Menzies, A. M.
    Long, G. V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S873 - S874
  • [7] Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
    Christiansen, Shelly Ann
    Swoboda, David
    Gardner, Kellie
    Rapisuwon, Suthee
    Atkins, Michael B.
    Gibney, Geoffrey Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] BRAF and MEK inhibitors in therapy of advanced melanoma
    Kosela, Hanna
    Switaj, Tomasz
    Rutkowski, Piotr
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (05): : 246 - 253
  • [9] Prognostic factors for efficacy of Ipilimumab used after anti-PD1 and/ or BRAF plus MEK inhibitors in melanoma patients: An Italian melanoma intergroup study
    Marconcini, R.
    Nuzzo, A.
    Manacorda, S.
    de Rosa, F.
    Fava, P.
    Astrua, C.
    Di Guardo, L. A.
    Raimondi, A.
    Stucci, S. L.
    Todisco, A.
    Cortellini, A.
    Bersanelli, M.
    Nigro, O.
    Palla, M.
    Palmieri, G.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 551 - 551
  • [10] Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
    Pires da Silva, Ines
    Zakria, Danny
    Ahmed, Tasnia
    Trojanello, Claudia
    Dimitriou, Florentia
    Allayous, Clara
    Gerard, Camille
    Zimmer, Lisa
    Lo, Serigne
    Michielin, Olivier
    Lebbe, Celeste
    Mangana, Johanna
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Carlino, Matteo
    Menzies, Alexander
    Long, Georgina
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
12345